SAWAI GROUP HOLDINGS Co.,Ltd. Q4 FY2026 earnings call

• Company Overview & Value Proposition

  • Sawai Group Holdings is a healthcare group centered on generic drug manufacturer Sawai Seiyaku, with 55 years of generic drug development and manufacturing experience, targeting to become a full-spectrum healthcare group beyond generic drugs.
  • Sawai Seiyaku is the largest prescription drug seller by volume in Japan, selling 1.6 billion tablets annually, and contributes an estimated 300 billion yen in annual national healthcare cost savings.
  • Generic drugs have the same active ingredient and efficacy as innovator drugs, priced at 30-40% of the original innovator drug price, and play a key role in controlling Japan's growing healthcare expenditure (currently 47 trillion yen total annual spending).

• Competitive Strengths

  • Strong R&D capability: Leverages decades of know-how to replicate unformulated manufacturing processes, owns patented proprietary formulation technologies (SAWAI HARMOTECH, QualityHug) that improve patient adherence (e.g. smaller tablets, water-free orally disintegrating tablets). Has a track record of successful patent challenge litigation to launch exclusive products ahead of competitors. Annual R&D expenditure is 10 billion to 12 billion yen, with 300 R&D staff out of 3,311 total employees as of December 2024.
  • Top-tier stable supply capability: Operates 7 domestic production bases with a current total production capacity of 20.5 billion tablets, has added 6.5 billion tablets of capacity through recent facility expansions. Has ranked 1st for 15 consecutive years in pharmacist popularity ranking for generic drug makers, primarily for its reliable supply.
  • Solid financial foundation: Has a history of early proactive capacity investment ahead of generic market expansion that drove past growth.

• Business Strategy

  • Core generic drug business: Focuses on low-molecular generics, prioritizes development of high-competitive-advantage products and exclusive launches to grow market share and profitability. Newly launched generic products have the highest profit margins, which decline gradually with annual drug price revisions.
  • Production capacity expansion: Targets to increase in-house production capacity to over 22 billion tablets by the end of the current mid-term plan (FY2027), and to 25 billion tablets by FY2030, to capture market growth from upcoming patent expirations and address industry-wide supply shortages.
  • New business investment: Invests in growth areas aligned with healthy longevity goals, including digital health, medical devices, and preventive health products. Current pipeline includes: personal health management app SaluDi, non-invasive neuromodulation devices, drinking reduction treatment app (launch planned FY2025), and NASH treatment app (launch planned FY2027).
  • Cash allocation: Plans to allocate ~190 billion yen of total capital (145 billion yen from operating cash flow + 45 billion yen from asset sales) over the 3-year mid-term plan, prioritizing R&D and capacity expansion investment. Plans 52 billion yen in total shareholder returns via share buybacks and dividends, switched shareholder return policy from payout ratio to 3%+ DOE, implemented a 10 yen dividend increase to 53 yen per share and a 33 billion yen share buyback in the current period.

1. Generic Pharmaceuticals (Core Segment): Current total annual sales reached 170 billion yen, holds 17% share of the domestic generic pharmaceutical market and 8.4% of the total prescription drug market (including innovator drugs), contributes nearly 100% of current revenue. 2. New Business Segment: Targeted sales of 1 billion yen by the final year of the mid-term management plan (Beyond 2027, ending FY2027), contributes less than 1% of planned total revenue.

• Market share targets: 21% domestic generic market share by FY2026, 25%+ share by FY2030, up from the current 17%.
• Mid-term management plan (Beyond 2027, ending FY2027) financial targets: 219 billion yen in generic drug segment revenue, 1 billion yen in new business revenue, 220 billion yen total consolidated revenue; 33 billion yen core operating profit; ROE ≥ 10%, ROIC ≥ 8%.
• Targeted timing of stronger growth: FY2026 (ending March 2026) is expected to see increased free cash flow and profit, but will not be a full recovery/harvest period; stronger large-scale growth is targeted from FY2027 (ending March 2027) onward.
• New product pipeline: Continues to plan annual launches of new generic drugs based on consistent upcoming patent expirations through 2030, with a total available market of 1.8 trillion yen (innovator drug price base) of low-molecular generics coming off patent within 6 years.

• Industry-wide drug supply shortage: Around 14% of all prescription drugs are currently in shipment suspension or restricted supply, driven by prior factory shutdowns from regulatory violations at peer firms, and ~30% of all generic drug SKUs are unprofitable. Supply shortages are unlikely to resolve quickly, as most smaller peers cannot afford to increase production of unprofitable products, and product transfer regulatory approval takes 1 year to complete.
• Rising R&D costs: Development costs for low-molecular generics have risen from 200 million to 300 million yen per product historically to 500 million to 1 billion yen per product currently due to higher difficulty and larger molecular weights, squeezing profitability for smaller industry players.
• Continuous drug price erosion: Generic drug prices decline steadily via biennial drug price revisions, with internal generic oral drug prices falling to half of 10-year-ago levels, and manufacturers cannot pass through rising raw material and production costs to consumers.
• Industry consolidation pressure: The Japanese government is promoting industry consolidation via policy incentives for stable supply, which is expected to reduce the number of generic drug manufacturers from ~190 currently to 5-10 long-term players, meaning most smaller current players will be forced to exit the market.

Q: Will you pursue M&A of struggling smaller generic drug makers as part of industry consolidation? / A: Sawai has no plans to acquire entire small generic companies. Most small targets only have 50-100 SKUs, many of which rely on deep discounting to gain share, which would create pricing conflicts with Sawai's strategy of appropriate pricing to fund long-term investment and capacity. Small acquisition targets also offer no meaningful capacity addition. If pursuing M&A, Sawai prefers acquiring existing underutilized factories from innovator drug companies, which already have GMP-qualified staff and existing infrastructure, saving 2-3 years of construction and training time and lower total cost compared to building a new factory from scratch, which would currently cost 40-50 billion yen for a new facility.

Q: What is the most profitable market dynamic for generic drug makers? / A: Newly launched products have the highest profit margins, which decline over time as drug prices are revised. While large blockbusters with expiring patents draw many competitors, the number of firms capable of developing these products has shrunk from 20-30 historically to under 10 currently. The most attractive opportunities are smaller to mid-sized markets with only 1-2 competitors, where Sawai can be first to market, as this delivers far higher per-company revenue and profit than crowded blockbuster segments. Sawai's R&D capability gives it a strong advantage in accessing these opportunities.

Q: Why are you investing resources into new non-generic businesses? / A: The investments align with Sawai's long-term vision of becoming a comprehensive healthcare company that contributes to public health beyond drug treatment, addressing growing demand for preventive and pre-disease health management aligned with Japan's policy push for healthy longevity. The new businesses leverage synergies with Sawai's existing brand and healthcare industry expertise, and are in early stages of development with clear commercialization timelines for initial products starting in 2025.

Q: What are Sawai's greatest competitive advantages compared to peers? / A: The two core strengths are R&D capability and stable supply capability. R&D capability drives the profit margin difference vs peers: Sawai uses its patent analysis and formulation expertise to launch exclusive products ahead of competitors every year, which delivers higher margins and faster share growth. Supply capability drives market reputation: Sawai has ranked 1st for 15 consecutive years in pharmacist trust rankings, with supply reliability cited as the top reason for this rating, which directly translates to higher market share.